+1 (704) 266-3234

Melanoma Diagnostics And Therapeutics Market - Growth, Trends, And Forecast (2020 - 2025)

Published on: Feb 2020 | From USD $4250 | Published By: MORDOR INTELLIGENCE | Number Of Pages: 114

The melanoma diagnostics and therapeutics market is estimated to show good growth due to the increasing incidences of melanoma cases, rising governments initiatives for early detection and skin cancer treatment and rising technological advancements.

There has been a rapid increase in the melanoma cases that is found to be one of the major causes of morbidity and mortality in the US. Melanoma is one of the most common types of cancer in men and women. Among young adults, it is the second most common invasive cancer. According to WHO statistics, there are more than two million people that develops non-melanoma skin cancer, and around 132,000 people that develop melanoma.

Also according to the Skin Cancer Foundation, one in every five Americans is likely to develop a kind of skin cancer during his/her lifetime. Furthermore, the American cancer society estimates 91,270 new cases of melanoma in the United States in 2018 alone. Therefore the rising number of cases of melanoma will eventually lead to the high CAGR for the melanoma diagnostics and therapeutics market.

Key Market Trends

Immune Therapy is Anticipated to be the Dominant in Therapeutics Segment during the Forecast Period

Immunotherapy is the use of medicines to stimulate a person immune system to recognize and destroy cancer cells effectively. There are several types of immunotherapies available that can be used to treat melanoma cancer.

Immunotherapy is found to hold the largest share that can be attributed to the effectiveness of drugs used in immunotherapy and an increase in their approvals. There are currently many FDA-approved immunotherapy options for melanoma that helps in the growth of the market. There have also many advances in using immunotherapy drugs known as checkpoint inhibitors to treat melanoma. Thus the strong emerging pipeline for melanoma treatment is expected to drive the immunotherapy segment over the forecast period.

North America Dominates the Melanoma Diagnostics and Therapeutics Market

North America holds a dominant share of the market owing to the rising incidence of melanoma and other skin cancers cases in the region. According to the CDC, over 71,943 people were affected by melanoma in 2013. As per the American Cancer Society, this number is expected to go up to 87,100 cases in 2017. These statistics highlight the need for drugs that help in the management of melanoma over the coming years.

The United States government has also developed favorable reimbursement policies for treatment of melanoma diseases that is an attempt to fulfil unmet patient needs. This is expected to provide a healthy platform for growth to the North American market. Furthermore, the presence of numerous new players is expected to drive the overall market.

Competitive Landscape

The market is highly competitive in nature, with many key players involved in market expansion, partnerships, new product development, and R&D to increase market penetration. There are also several products are under clinical trials which are expected to receive approval and thus the market is likely to continue witnessing high competitive rivalry over the forecast period.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Melanoma Cases
4.2.2 Rising Governments Initiatives for Early Detection and Skin Cancer Treatment
4.2.3 Rising Technological Advancements
4.3 Market Restraints
4.3.1 High Cost Associated with the Therapy
4.3.2 Stringent Regulatory Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product Type
5.1.1 By Diagnostics Dermatoscopy Devices Biopsy Devices
5.1.2 By Therapeutics Chemotherapy Biological Therapy Targeted Therapy Immune Therapy
5.2 Geography
5.2.1 North America US Canada Mexico
5.2.2 Europe Germany UK France Italy Spain Rest of Europe
5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Diagnostics
6.1.2 Amgen, Inc.
6.1.3 AstraZeneca PLC
6.1.4 Bayer AG
6.1.5 Bristol-Myers Squibb
6.1.6 Daiichi Sankyo Company Limited
6.1.7 F. Hoffman-La Roche Ltd.
6.1.8 GlaxoSmithKline PLC
6.1.9 Merck & Co., Inc
6.1.10 Novartis AG


Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

The market engineered data is verified and validated by a number of experts, both in-house and external.

After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $4250
USD $4750
USD $6000
USD $7500


  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.